Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.

Journal:: Journal of Clinical Oncology
Published:: 2025-08-09
DOI:: 10.1200/jco-25-00618
Affiliations:: 26
Authors:: 22

Go to article

Institutions	Authors	Share
Miami Cancer Institute, United States of America (USA)	2.000000	0.09
New York-Presbyterian Hospital, United States of America (USA)	1.500000	0.07
NRG Oncology Statistical and Data Management Center (SDMC), United States of America (USA)	1.500000	0.07
NYU Laura and Isaac Perlmutter Cancer Center, United States of America (USA)	1.500000	0.07
Columbia University Irving Medical Center (CUIMC), CU, United States of America (USA)	1.000000	0.05
WellSpan Health, United States of America (USA)	1.000000	0.05
Piedmont Healthcare, United States of America (USA)	1.000000	0.05
NYU Langone Health, United States of America (USA)	1.000000	0.05
Herbert Irving Comprehensive Cancer Center (HICCC), United States of America (USA)	1.000000	0.05
NIH National Cancer Institute (NCI), United States of America (USA)	1.000000	0.05
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.05
NIH Clinical Center, United States of America (USA)	1.000000	0.05
Northwestern University (NU), United States of America (USA)	1.000000	0.05
Northwestern Medicine, United States of America (USA)	1.000000	0.05
The University of Chicago (UChicago), United States of America (USA)	1.000000	0.05
Saint Luke's Hospital of Kansas City, United States of America (USA)	0.500000	0.02
Kaiser Permanente Los Angeles Medical Center, United States of America (USA)	0.500000	0.02
M Health Fairview, United States of America (USA)	0.500000	0.02
American College of Radiology (ACR), United States of America (USA)	0.500000	0.02
Hackensack University Medical Center (Hackensack UMC), United States of America (USA)	0.500000	0.02
Metro-Minnesota Community Oncology Research Consortium (MMCORC), United States of America (USA)	0.500000	0.02
NCI Community Oncology Research Program - Kansas City (NCORP-KC), United States of America (USA)	0.500000	0.02
Sandra and Edward Meyer Cancer Center, United States of America (USA)	0.500000	0.02
UW Medicine, United States of America (USA)	0.500000	0.02

Interested in Oncology and Carcinogenesis?

Research leaders

2026 Research Leaders

The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their output in Nature Index journals in 2025.

Access free

Latest supplement

Nature Index 2026 Nanoscience and nanotechnology

From programmable RNA architectures to next-generation materials for energy and healthcare, researchers are harnessing the unusual properties of the nanoscale to tackle some of society's biggest challenges. This supplement explores the discoveries that are driving the field, the hurdles that remain and the institutions that are leading in nanoscience and nanotechnology research.

Access free

Nature Index 2026 Chemistry

Chemistry research is undergoing a period of transformation, driven by new technologies and mounting environmental pressures. In this supplement, we explore the trends behind China’s extraordinary rise in chemistry output, and why efforts to curb the use of PFASs are accelerating worldwide. We also look at the innovations that could redefine how chemicals are designed, produced and recycled.

Access free

Research highlights of partners

New effect of viruses on brains discovered

The University of Queensland (UQ)
30 Nov 2023
Ants’ venom contains neurotoxins

The University of Queensland (UQ)
31 Oct 2023
How the brain wakes up after anaesthesia

Southern University of Science and Technology (SUSTech)
31 Oct 2023

Research highlights